Fc Receptor Assay for HLA Antibody Pathogenicity Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays, such as the C1q assay, are inadequate for detecting the pathogenic potential of HLA antibodies, especially at low or moderate levels, and do not provide a functional assessment of their immune-protective or pathogenic capacity, which is crucial for preventing and managing antibody-mediated rejection in transplant patients.
Innovation Solution
A method involving contacting a biological sample with a substrate conjugated to an HLA antigen and an Fc receptor operatively linked to a detectable label, allowing for the detection of antibody binding and assessing the pathogenic or beneficial nature of HLA antibodies through fluorescence measurement on platforms like Luminex.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If C1q assay is used to detect HLA antibody function, then complement activation can be assessed, but sensitivity is insufficient for low or moderate concentration antibodies and functional assessment is limited
Solution Approach 1:
The patent introduces Fc receptors as an intermediary component to detect antibody binding. Instead of directly measuring complement activation (C1q assay), the assay uses Fc receptors bound to detectable labels as mediators to indirectly detect HLA antibodies, significantly improving sensitivity for low-concentration antibodies while maintaining assay feasibility
Solution Approach 2:
The patent replaces the complement activation mechanism (biological cascade) with a direct binding mechanism (antibody-Fc receptor interaction). This substitution simplifies the detection principle from a complex multi-step complement cascade to a direct one-step binding assay, improving both sensitivity and ease of operation
2Reliability
If invasive biopsy procedures are performed to diagnose AMR, then accurate diagnosis can be obtained, but patient discomfort and procedural risk increase
Solution Approach 1:
The patent enables the assay to detect and diagnose AMR using readily available serum samples without requiring invasive tissue biopsy. The Fc receptor binding assay self-sufficiently provides diagnostic information from blood samples, eliminating the need for harmful invasive procedures while maintaining diagnostic reliability
3Loss of information
If HLA SAB assay is used to detect anti-HLA antibodies, then antibody presence can be detected, but functional assessment of pathogenic capacity is not provided
Solution Approach 1:
The patent merges two functions into a single assay: antibody detection (from HLA SAB assay) and functional assessment (through Fc receptor binding). By combining these functions, the assay simultaneously identifies antibody presence and evaluates pathogenic capacity, preventing loss of functional information without substantially increasing procedural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD64 Fc receptor assay demonstrates superior sensitivity and correlation with clinical outcomes, including Banff component scoring and allograft survival, providing a more accurate assessment of HLA antibody pathogenicity compared to traditional C1q assays.
Implementation Method 1
Interactions of antibodies with Fc receptors mediates a substantial proportion of these widely varying functions
Implementation Method 2
assessing the pathogenic or beneficial nature of HLA antibodies through fluorescence measurement
Data Source
AI summary
Disclosed are kits and methods for determining the presence or absence of an antibody of interest in a biological sample of a subject. In particular, the methods may detect either pathological or beneficial antibodies. The method may include the step of contacting a biological sample from a subject with a substrate conjugated to an antigen and an Fc receptor operatively linked to a detectable label. Detection of the label may indicate the presence or absence of an antibody of interest.